β-Glucan supplementation, allergy symptoms, and quality of life in self-described ragweed allergy sufferers

Shawn M Talbott, Julie A Talbott, Tracy L Talbott, Elaine Dingler, Shawn M Talbott, Julie A Talbott, Tracy L Talbott, Elaine Dingler

Abstract

This randomized, placebo-controlled, double-blind study compared the effects of daily supplementation for 4 week with 250 mg Wellmune WGP® β-1,3/1,6-Glucan (WGP) with placebo 250 mg/day (rice flour) on physical and psychological health attributes of self-described "moderate" ragweed allergy sufferers. Study participants (mean age = 36 ± 9 year; range 18-53 year) were recruited before the beginning of ragweed season (September) in Northeastern Ohio. Serum IgE concentration, allergy symptoms [via self-report, Visual Analog Scale (VAS), and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)], psychological well-being [Profile of Mood States (POMS)], and physical function (RAND SF-36 Medical Outcomes Study) were measured immediately prior to and after supplementation with WGP (n = 24) or placebo (n = 24) for 4 weeks. Data were analyzed using repeated measures analyses of variance (ANOVA). Compared with placebo, WGP reduced total allergy symptoms (28%), symptom severity (52%), and symptom rating on the VAS (37%) (P < 0.05), but had no effect on serum IgE levels. As measured by the POMS, WGP increased participants' rating of vigor (10%), but reduced tension (34%), depression (45%), anger (41%), fatigue (38%), and confusion (34%) (P < 0.05). Study participants given WGP reported increased physical health (11%), energy (19%), and emotional well-being (7%) compared with study participants given the placebo (RAND SF-36 Medical Outcomes Study). The WGP group also reported decreased sleep problems (53%), reduced nasal symptoms (59%), eye symptoms (57%), non-nasal symptoms (50%), activities (53%), emotions (57%), and improved quality of life (QOL) (56%), as well as improved global mood state (13%). Supplementation with WGP for 4 weeks improved allergy symptoms, overall physical health, and emotional well-being compared with placebo in self-described "moderate" ragweed allergy sufferers during ragweed allergy season.

Keywords: Allergy; IgE; allergy symptom; quality of life; ragweed; rhinitis; β-glucan.

Figures

Figure 1
Figure 1
Flow of study participants
Figure 2
Figure 2
Allergy Symptoms. When compared with placebo treatment with Wellmune WGP® for 4 weeks, there was a reduction observed in total number of allergy symptoms (28%), in symptom severity (52%),and in the rating of symptoms on the VAS (37%).*P < 0.05 compared with placebo.
Figure 3
Figure 3
Profile of Mood States. POMS factors improved from week 0 to week 4 following treatment with Wellmune WGP® including reduced tension (34%), depression (45%), anger (41%), fatigue (38%), confusion (34%), and increased vigor (10%). *P < 0.05. Treatment with placebo from week 0 to week 4 did not result in statistically significant improvements in these six POMS factors.
Figure 4
Figure 4
Global Mood States. The Global Mood State showed a 34% improvement (P < 0.05) following 4 weeks of treatment with Wellmune WGP. The placebo group did not show a significant improvement over the 4-week treatment period. A lower number is a “better” global mood state.
Figure 5
Figure 5
RAND SF-36 Medical Outcomes. After 4 weeks of treatment with Wellmune WGP®, there was an elevation in physical health (11%), energy (19%), and emotional well-being (7%), compared with placebo. *P < 0.05 compared with placebo.
Figure 6
Figure 6
Rhinoconjunctivitis Quality of Life. After 4 weeks of treatment with Wellmune WGP®, there was a reduction in sleep problems (53%), nasal symptoms (59%), and eye symptoms (57%) and an elevation in QOL (56%); *P < 0.05 compared with placebo.

References

    1. Adachi Y, Okazaki M, Ohno N, Yadomae T. Enhancement of cytokine production by macrophages stimulated with (1–>3)-b-D-glucan, grifolan (GRN), isolated from Grifola frondosa. Biol. Pharm. Bull. 1994;17(12):1554–1560.
    1. Ahren IL, Williams DL, Rice PJ, Forsgren A, Riesbeck K. The importance of a b-glucan receptor in the nonopsonic entry of nontypeable Haemophilus influenzae into human monocytic and epithelial cells. J. Infect. Dis. 2001;184(2):150–158.
    1. Akramiene D, Kondrotas A, Didziapetriene J, Kevelaitis E. Effects of beta-glucans on the immune system. Medicina (Kaunas) 2007;43(8):597–606.
    1. Arbes Jr SJ, Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J. Allergy Clin. Immunol. 2005;116(2):377–383.
    1. Austin JB, Kaur B, Anderson HR, Burr M, Harkins LS, Strachan DP. Hay fever, eczema, and wheeze: a nationwide UK study (ISAAC, international study of asthma and allergies in childhood) Arch. Dis. Child. 1999;81(3):225–230.
    1. Babineau TJ, Hackford A, Kenler A, Bistrian B, Forse RA, Fairchild PG. A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. Arch. Surg. 1994a;129(11):1204–1210.
    1. Babineau TJ, Marcello P, Swails W, Kenler A, Bistrian B, Forse RA. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann. Surg. 1994b;220(5):601–609.
    1. Bell S, Goldman VM, Bistrian BR, Arnold AH, Ostroff G, Forse RA. Effect of β-glucan from oats and yeast on serum lipids. Crit. Rev. Food Sci. Nutr. 1999;39(2):189–202.
    1. Biagini RE, MacKenzie BA, Sammons DL, Smith JP, Krieg EF, Robertson SA, et al. Latex specific IgE: performance characteristics of the IMMULITE 2000 3gAllergy assay compared with skin testing. Ann. Allergy Asthma Immunol. 2006;97(2):196–202.
    1. Boulet LP, Turcotte H, Laprise C, Lavertu C, Bedard PM, Lavoie A, et al. Comparative degree and type of sensitization to common indoor and outdoor allergens in subjects with allergic rhinitis and/or asthma. Clin. Exp. Allergy. 1997;27(1):52–59.
    1. Bousquet J, Dhivert H, Michel FB. Current trends in the management of allergic diseases. Allergy. 1994;49(18 Suppl):31–36.
    1. Bousquet J, vanCauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. 2001;108(5 Suppl):S147–S334.
    1. Bousquet PJ, Combescure C, Neukirch F, Klossek JM, Mechin H, Daures JP, et al. Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy. 2007;62(4):367–372.
    1. Browder W, Williams D, Pretus H, Olivero G, Enrichens F, Mao P, et al. Beneficial effect of enhanced macrophage function in the trauma patient. Ann. Surg. 1990;211(5):605–612.
    1. Brown GD. Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat. Rev. Immunol. 2006;6(1):33–43.
    1. Brown GD, Gordon S. Immune recognition. A new receptor for b-glucans. Nature. 2001;413(6851):36–37.
    1. Brown GD, Gordon S. Immune recognition of fungal β-glucans. Cell. Microbiol. 2005;7(4):471–479.
    1. Brown GD, Taylor PR, Reid DM, Willment JA, Williams DL, Martinez-Pomares L. Dectin-1 is a major b-glucan receptor on macrophages. J. Exp. Med. 2002;196(3):407–412.
    1. Brown GD, Herre J, Williams DL, Willment JA, Marshall AS, Gordon S. Dectin-1 mediates the biological effects of β-glucans. J. Exp. Med. 2003;197(9):1119–1124.
    1. Bukantz SC, Lockey RF. Adverse effects and fatalities associated with subcutaneous allergen immunotherapy. Clin. Allergy Immunol. 2004;18:711–727.
    1. Chen J, Seviour R. Medicinal importance of fungal b-(1–>3), (1–>6)-glucans. Mycol. Res. 2007;111(Pt 6):635–652.
    1. Cheung NK, Modak S, Vickers A, Knuckles B. Orally administered b-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol. Immunother. 2002;51(10):557–564.
    1. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. 2006;355(14):1445–1455.
    1. Damiani V, Di CM, Grappasonni G, Di DR, Dominici P. Efficacy of a new medical device based on colloidal silver and carbossimetyl beta glucan in treatment of upper airways disease in children. Minerva Pediatr. 2011;63(5):347–354.
    1. Delatte SJ, Evans J, Hebra A, Adamson W, Othersen HB, Tagge EP. Effectiveness of b-glucan collagen for treatment of partial-thickness burns in children. J. Pediatr. Surg. 2001;36(1):113–118.
    1. Dellinger EP, Babineau TJ, Bleicher P, Kaiser AB, Seibert GB, Postier RG, et al. Effect of PGG-glucan on the rate of serious postoperative infection or death observed after high-risk gastrointestinal operations. Betafectin Gastrointestinal Study Group. Arch. Surg. 1999;134(9):977–983.
    1. Di Carlo FJ, Fiore JV. On the composition of zymosan. Science. 1958;127(3301):756–757.
    1. Douwes J. (1–>3)-b-D-glucans and respiratory health: a review of the scientific evidence. Indoor Air. 2005;15(3):160–169.
    1. Driscoll M, Hansen R, Ding C, Cramer DE, Yan J. Therapeutic potential of various b-glucan sources in conjunction with anti-tumor monoclonal antibody in cancer therapy. Cancer Biol. Ther. 2009;8(3):218–225.
    1. Du Buske LM, Ling CJ, Sheffer AL. Special problems regarding allergen immunotherapy. Immunol. Allergy Clin. North Am. 1992;12:145–175.
    1. Feldman S, Schwartz HI, Kalman DS, Mayers A, Kohrman HM, Clemens R, et al. Randomized phase II clinical trials of Wellmune WGP® for immune support during cold and flu season. J. Appl. Res. 2009;9(1–2):30–42.
    1. de Felippe JJ, SilvaJunior daRochae, Maciel FM, Soares AM, Mendes NF. Infection prevention in patients with severe multiple trauma with the immunomodulator b 1–3 polyglucose (glucan) Surg. Gynecol. Obstet. 1993;177(4):383–388.
    1. Frenz DA, Palmer MA, Hokanson JM, Scamehorn RT. Seasonal characteristics of ragweed pollen dispersal in the United States. Ann. Allergy Asthma Immunol. 1995;75(5):417–422.
    1. Hahn PY, Evans SE, Kottom TJ, Standing JE, Pagano RE, Limper AH. Pneumocystis carinii cell wall b-glucan induces release of macrophage inflammatory protein-2 from alveolar epithelial cells via a lactosylceramide-mediated mechanism. J. Biol. Chem. 2003;278(3):2043–2050.
    1. Hallen H, Djupesland P, Kramer J, Toll K, Graf P. Evaluation of a new method for assessing symptoms. ORL J. Otorhinolaryngol. Relat. Spec. 2001;63(2):92–95.
    1. Hays RD, Sherbourne CD, Mazel RM. 36-Item Health Survey 1.0. Health Econ. 1993;2(3):217–227.
    1. Hazama S, Watanabe S, Ohashi M, Yagi M, Suzuki M, Matsuda K, et al. Efficacy of orally administered superfine dispersed lentinan (b-1,3-glucan) for the treatment of advanced colorectal cancer. Anticancer Res. 2009;29(7):2611–2617.
    1. Holgate ST. The epidemic of allergy and asthma. Nature. 1999;402(6760 Suppl):B2–B4.
    1. Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, et al. Mechanism by which orally administered b-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J. Immunol. 2004;173(2):797–806.
    1. Hornblow AR, Kidson MA. The visual analogue scale for anxiety: a validation study. Aust. N. Z. J. Psychiatry. 1976;10(4):339–341.
    1. Huang SK, Xiao HQ, Kleine-Tebbe J, Paciotti G, Marsh DG, Lichtenstein LM. IL-13 expression at the sites of allergen challenge in patients with asthma. J. Immunol. 1995;155(5):2688–2694.
    1. Ikewaki N, Fujii N, Onaka T, Ikewaki S, Inoko H. Immunological actions of Sophy b-glucan (b-1,3–1,6 glucan), currently available commercially as a health food supplement. Microbiol. Immunol. 2007;51(9):861–873.
    1. Eagan, MN: Biothera, Inc; 2008. GRAS Notice for Yeast Beta-Glucan [GRN 239]
    1. Iossifova YY, Reponen T, Bernstein DI, Levin L, Kalra H, Campo P, et al. House dust (1–3)-b-D-glucan and wheezing in infants. Allergy. 2007;62(5):504–513.
    1. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin. Exp. Allergy. 1991;21(1):77–83.
    1. Juniper EF, Willms DG, Guyatt GH, Ferrie PJ. Aqueous beclomethasone dipropionate nasal spray in the treatment of seasonal (ragweed) rhinitis. CMAJ. 1992;147(6):887–892.
    1. Juniper EF, Guyatt GH, Griffith LE, Ferrie PJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J. Allergy Clin. Immunol. 1996;98(4):843–845.
    1. Kataoka H, Shimura T, Mizoshita T, Kubota E, Mori Y, Mizushima T, et al. Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life. Hepatogastroenterology. 2009;56(90):547–550.
    1. Kay AB. Allergy and allergic diseases. First of two parts. N. Engl. J. Med. 2001a;344(1):30–37.
    1. Kay AB. Allergy and allergic diseases. Second of two parts. N. Engl. J. Med. 2001b;344(2):109–113.
    1. Kim HS, Hong JT, Kim Y, Han SB. Stimulatory effect of b-glucans on immune cells. Immune Netw. 2011;11(4):191–195.
    1. Kirmaz C, Bayrak P, Yilmaz O, Yuksel H. Effects of glucan treatment on the Th1/Th2 balance in patients with allergic rhinitis: a double-blind placebo-controlled study. Eur. Cytokine Netw. 2005;16(2):128–134.
    1. Kougias P, Wei D, Rice PJ, Ensley HE, Kalbfleisch J, Williams DL, et al. Normal human fibroblasts express pattern recognition receptors for fungal (1–>3)-b-D-glucans. Infect. Immun. 2001;69(6):3933–3938.
    1. Kurashige S, Akuzawa Y, Endo F. Effects of Lentinus edodes,Grifola frondosaPleurotus ostreatus administration on cancer outbreak, and activities of macrophages and lymphocytes in mice treated with a carcinogen, N-butyl-N-butanolnitrosoamine. Immunopharmacol. Immunotoxicol. 1997;19(2):175–183.
    1. Ladanyi A, Timar J, Lapis K. Effect of lentinan on macrophage cytotoxicity against metastatic tumor cells. Cancer Immunol. Immunother. 1993;36(2):123–126.
    1. Lebron F, Vassallo R, Puri V, Limper AH. Pneumocystis carinii cell wall b-glucans initiate macrophage inflammatory responses through NF-kB activation. J. Biol. Chem. 2003;278(27):25001–25008.
    1. Lehne G, Haneberg B, Gaustad P, Johansen PW, Preus H, Abrahamsen TG. Oral administration of a new soluble branched b-1,3-D-glucan is well tolerated and can lead to increased salivary concentrations of immunoglobulin A in healthy volunteers. Clin. Exp. Immunol. 2005;143(1):65–69.
    1. Leplege A, Mesbah M, Marquis P. Preliminary analysis of the psychometric properties of the French version of an international questionnaire measuring the quality of life: the MOS SF-36 (version 1.1) Rev. Epidemiol. Sante Publique. 1995;43(4):371–379.
    1. Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F. Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am. J. Respir. Crit. Care Med. 2000;162 4 Pt 1:1391–1396.
    1. Li B, Allendorf DJ, Hansen R, Marroquin J, Ding C, Cramer DE, et al. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. J Immunol. 2006;177(3):1661–1669.
    1. Linder A. Symptom scores as measures of the severity of rhinitis. Clin Allergy. 1988;18(1):29–37.
    1. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST) J. Allergy Clin. Immunol. 1987;79(4):660–677.
    1. Lowe EP, Wei D, Rice PJ, Li C, Kalbfleisch J, Browder IW, et al. Human vascular endothelial cells express pattern recognition receptors for fungal glucans which stimulates nuclear factor kB activation and interleukin 8 production. Winner of the Best Paper Award from the Gold Medal Forum. Am. Surg. 2002;68(6):508–517.
    1. McCann F, Carmona E, Puri V, Pagano RE, Limper AH. Macrophage internalization of fungal b-glucans is not necessary for initiation of related inflammatory responses. Infect. Immun. 2005;73(10):6340–6349.
    1. McHorney CA, Jr Ware JE. Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med. Care. 1994;32(1):40–66.
    1. McNair D, Loor M, Droppleman L. San Diego, CA: Educational and Industrial Testing Service; 1971. Manual for the profile of mood states.
    1. McNair D, Heuchert J, Shilony E. 2003. Profile of Mood States Bibliography 1964–2002 Available from: [cited 18 December 2008].
    1. Meltzer EO. Quality of life in adults and children with allergic rhinitis. J. Allergy Clin. Immunol. 2001;108(1 Suppl):S45–S53.
    1. Murphy EA, Davis JM, Carmichael MD. Immune modulating effects of β-glucan. Curr. Opin. Clin. Nutr. Metab. Care. 2010;13(6):656–661.
    1. Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K. A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group. Hepatogastroenterology. 1999;46(28):2662–2668.
    1. Nathan RA. Pharmacotherapy for allergic rhinitis: a critical review of leukotriene receptor antagonists compared with other treatments. Ann. Allergy Asthma Immunol. 2003;90(2):182–190.
    1. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc. 2007;28(1):3–9.
    1. Airborne allergens: something in the air. Bethesda, MD: National Institutes of Health; 2003. Report No.: NIH Publication No. 03-7045. National Institute of Allergy and Infectious Diseases.
    1. Nicolosi R, Bell SJ, Bistrian BR, Greenberg I, Forse RA, Blackburn GL. Plasma lipid changes after supplementation with b-glucan fiber from yeast. Am. J. Clin. Nutr. 1999;70(2):208–212.
    1. Oswalt ML, Marshall GD. Ragweed as an example of worldwide allergen expansion. Allergy Asthma Clin. Immunol. 2008;4(3):130–135.
    1. Pawankar R, Mori S, Ozu C, Kimura S. Overview on the pathomechanisms of allergic rhinitis. Asia Pac. Allergy. 2011;1(3):157–167.
    1. Pearson A, Lux A, Krieger M. Expression cloning of dSR-CI, a class C macrophage-specific scavenger receptor from Drosophila melanogaster. Proc. Natl. Acad. Sci. U.S.A. 1995;92(9):4056–4060.
    1. Pongdee T. Ragweed plants packed with pollen. 2011. AAAAI. Available at: (accessed 26 January 2012)
    1. Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain. 1983;17(1):45–56.
    1. Ramakers JD, Volman JJ, Biorklund M, Onning G, Mensink RP, Plat J. Fecal water from ileostomic patients consuming oat β-glucan enhances immune responses in enterocytes. Mol. Nutr. Food Res. 2007;51(2):211–220.
    1. Rice PJ, Kelley JL, Kogan G, Ensley HE, Kalbfleisch JH, Browder IW, et al. Human monocyte scavenger receptors are pattern recognition receptors for (1–>3)-beta-D-glucans. J. Leukoc. Biol. 2002;72(1):140–146.
    1. Rice PJ, Adams EL, Ozment-Skelton T, Gonzalez AJ, Goldman MP, Lockhart BE, et al. Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge. J. Pharmacol. Exp. Ther. 2005;314(3):1079–1086.
    1. Riggi SJ, Di Luzio NR. Identification of a reticuloendothelial stimulating agent in zymosan. Am. J. Physiol. 1961;200:297–300.
    1. Romagnani S, Maggi E, Parronchi P, Macchia D, Piccinni MP, Ricci M. Increased numbers of Th2-like CD4 + T cells in target organs and in the allergen-specific repertoire of allergic patients. Possible role of IL-4 produced by non-T cells. Int. Arch. Allergy Appl. Immunol. 1991;94(1–4):133–136.
    1. Ross GD, Cain JA, Myones BL, Newman SL, Lachmann PJ. Specificity of membrane complement receptor type three (CR3) for β-glucans. Complement. 1987;4(2):61–74.
    1. Rylander R, Norrhall M, Engdahl U, Tunsater A, Holt PG. Airways inflammation, atopy, and (1–> 3)-β-D-glucan exposures in two schools. Am. J. Respir. Crit. Care Med. 1998;158(5 Pt 1):1685–1687.
    1. Sarinho E, Medeiros D, Schor D, Rego SA, Sales V, Motta ME, et al. Production of interleukin-10 in asthmatic children after β-1-3-glucan. Allergol. Immunopathol. (Madr.) 2009;37(4):188–192.
    1. Shah VB, Huang Y, Keshwara R, Ozment-Skelton T, Williams DL, Keshvara L. β glucan activates microglia without inducing cytokine production in Dectin-1-dependent manner. J. Immunol. 2008;180(5):2777–2785.
    1. Shimizu K, Watanabe S, Watanabe S, Matsuda K, Suga T, Nakazawa S, et al. Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer. Hepatogastroenterology. 2009;56(89):240–244.
    1. 7Suzuki I, Tanaka H, Kinoshita A, Oikawa S, Osawa M, Yadomae T. Effect of orally administered b-glucan on macrophage function in mice. Int. J. Immunopharmacol. 1990;12(6):675–684.
    1. Szabo Z, Szilasi M, Brugos L, Szanto S, Kovacs I, Szeles M, et al. Differences in the changes of allergen-specific IgE serum levels and the chemiluminescence of peripheral blood phagocytes in patients with allergic rhinoconjunctivitis during the ragweed season. Immunol. Lett. 2000;74(3):201–205.
    1. Taylor PR, Brown GD, Reid DM, Willment JA, Martinez-Pomares L, Gordon S, et al. The β-glucan receptor, dectin-1, is predominantly expressed on the surface of cells of the monocyte/macrophage and neutrophil lineages. J. Immunol. 2002;169(7):3876–3882.
    1. Thornton BP, Vetvicka V, Pitman M, Goldman RC, Ross GD. Analysis of the sugar specificity and molecular location of the b-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18) J. Immunol. 1996;156(3):1235–1246.
    1. Tsoni SV, Brown GD. β-Glucans and dectin-1. Ann. N. Y. Acad. Sci. 2008;1143:45–60.
    1. Tsukada C, Yokoyama H, Miyaji C, Ishimoto Y, Kawamura H, Abo T. Immunopotentiation of intraepithelial lymphocytes in the intestine by oral administrations of β-glucan. Cell. Immunol. 2003;221(1):1–5.
    1. 2008. U.S. Food and Drug Administration Agency Response Letter GRAS Notice No. GRN 000239. CFSAN. Available from: (accessed 31 January 2012).
    1. Vassallo R, Standing J, Limper AH. β-glucan from Pneumocystis carinii stimulates TNF a release from alveolar macrophages. J. Eukaryot. Microbiol. 1999;46(5):145S.
    1. Vassallo R, Standing JE, Limper AH. Isolated Pneumocystis carinii cell wall glucan provokes lower respiratory tract inflammatory responses. J. Immunol. 2000;164(7):3755–3763.
    1. Vetvicka V, Yvin JC. Effects of marine β-1,3 glucan on immune reactions. Int. Immunopharmacol. 2004;4(6):721–730.
    1. Volman JJ, Ramakers JD, Plat J. Dietary modulation of immune function by β-glucans. Physiol. Behav. 2008;94(2):276–284.
    1. Ware Jr JE. Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care. 1992;30(6):473–483.
    1. Weitberg AB. A phase I/II trial of beta-(1,3)/(1,6) D-glucan in the treatment of patients with advanced malignancies receiving chemotherapy. J. Exp. Clin. Cancer Res. 2008;27:40.
    1. Willment JA, Marshall AS, Reid DM, Williams DL, Wong SY, Gordon S, et al. The human β-glucan receptor is widely expressed and functionally equivalent to murine Dectin-1 on primary cells. Eur. J. Immunol. 2005;35(5):1539–1547.
    1. Wooles WR, Diluzio NR. Reticuloendothelial function and the immune response. Science. 1963;142(3595):1078–1080.
    1. Wopfner N, Gadermaier G, Egger M, Asero R, Ebner C, Jahn-Schmid B. The spectrum of allergens in ragweed and mugwort pollen. Int. Arch. Allergy Immunol. 2005;138(4):337–346.
    1. Yamada J, Hamuro J, Hatanaka H, Hamabata K, Kinoshita S. Alleviation of seasonal allergic symptoms with superfine β-1,3-glucan: a randomized study. J. Allergy Clin. Immunol. 2007;119(5):1119–1126.
    1. Yoon TJ, Kim TJ, Lee H, Shin KS, Yun YP, Moon WK, et al. Anti-tumor metastatic activity of b-glucan purified from mutated Saccharomyces cerevisiae. Int. Immunopharmacol. 2008;8(1):36–42.
    1. Yoshino S, Watanabe S, Imano M, Suga T, Nakazawa S, Hazama S, et al. Improvement of QOL and prognosis by treatment of superfine dispersed lentinan in patients with advanced gastric cancer. Hepatogastroenterology. 2010;57(97):172–177.
    1. Young MC. Rhinitis, sinusitis, and polyposis. Allergy Asthma Proc. 1998;19(4):211–218.
    1. Zanon P, Chiodini E, Berra D. Allergy to ragweed in northern Italy and prevention strategies. Monaldi Arch. Chest Dis. 2002;57(2):144–146.
    1. Zhang K, Petty HR. Influence of polysaccharides on neutrophil function: specific antagonists suggest a model for cooperative saccharide-associated inhibition of immune complex-triggered superoxide production. J. Cell. Biochem. 1994;56(2):225–235.
    1. Zimmerman JW, Lindermuth J, Fish PA, Palace GP, Stevenson TT, DeMong DE. A novel carbohydrate-glycosphingolipid interaction between a β-(1–3)-glucan immunomodulator, PGG-glucan, and lactosylceramide of human leukocytes. J. Biol. Chem. 1998;273(34):22014–22020.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren